Special Issue

New Insights into Kinase Inhibitors II

Message from the Guest Editor

This issue is a continuation of the previous successful Special Issue "New Insights into Kinase Inhibitors".

In the last 30 years, kinases have been widely studied as drug targets to inhibit proliferation and angiogenesis in cancer therapy. Kinase inhibitors now represent one of the major classes of chemotherapeutics, with 52 kinase inhibitors having been approved as anticancer agents.

This Special Issue will highlight new insights into the discovery of new kinase inhibitors, from the investigation of new targets to the identification of novel small molecules. Contributions to this issue, both in the form of original articles or reviews, may focus on powerful strategies and technological advances in the synthesis of more efficient and selective compounds, new strategies to overcome kinase inhibitors resistance, and improvements regarding the use of kinase inhibitors in oncology and other pathologies, in which therapeutic combinations with less toxic and off-target effects are considered.

Guest Editor

Dr. Roberta Bortolozzi

- 1. Experimental Pharmacology Laboratory, Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy
- 2. Dipartimento Salute della Donna e del Bambino, Università degli Studi di Padova, Padua, Italy

Deadline for manuscript submissions

closed (31 March 2025)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/123384

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

